294 related articles for article (PubMed ID: 25882566)
1. Targeted therapy in advanced bladder cancer: what have we learned?
Jordan EJ; Iyer G
Urol Clin North Am; 2015 May; 42(2):253-62, ix. PubMed ID: 25882566
[TBL] [Abstract][Full Text] [Related]
2. Targeting FGFR in bladder cancer: ready for clinical practice?
De Keukeleire S; De Maeseneer D; Jacobs C; Rottey S
Acta Clin Belg; 2020 Feb; 75(1):49-56. PubMed ID: 31671027
[No Abstract] [Full Text] [Related]
3. Novel therapeutic targets in advanced urothelial carcinoma.
Rouanne M; Loriot Y; Lebret T; Soria JC
Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for the optimal management of early and advanced urothelial carcinoma.
Castellano D; Carles J; Esteban E; Trigo JM; Climent MÁ; Maroto JP; del Muro XG; Font A; Paz-Ares L; Arranz JÁ; Bellmunt J
Cancer Treat Rev; 2012 Aug; 38(5):431-41. PubMed ID: 22116017
[TBL] [Abstract][Full Text] [Related]
6. [Molecular Characterisation of Urothelial Bladder Cancer: Will it Improve Patient Care?].
Erben P; Hartmann A; Bolenz C
Aktuelle Urol; 2015 May; 46(3):227-35. PubMed ID: 26077307
[TBL] [Abstract][Full Text] [Related]
7. Molecular and histopathology directed therapy for advanced bladder cancer.
Alifrangis C; McGovern U; Freeman A; Powles T; Linch M
Nat Rev Urol; 2019 Aug; 16(8):465-483. PubMed ID: 31289379
[TBL] [Abstract][Full Text] [Related]
8. Genomics and Immunomics in the Treatment of Urothelial Carcinoma.
Mollica V; Massari F; Rizzo A; Ferrara R; Menta AK; Adashek JJ
Curr Oncol; 2022 May; 29(5):3499-3518. PubMed ID: 35621673
[TBL] [Abstract][Full Text] [Related]
9. Molecular biology and targeted therapies for urothelial carcinoma.
Seront E; Machiels JP
Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
[TBL] [Abstract][Full Text] [Related]
10. Emerging Targeted Therapy for Bladder Cancer.
Thibault C; Loriot Y
Hematol Oncol Clin North Am; 2021 Jun; 35(3):585-596. PubMed ID: 33958152
[TBL] [Abstract][Full Text] [Related]
11. Individualized management of advanced bladder cancer: Where do we stand?
Burgess EF
Urol Oncol; 2015 Apr; 33(4):187-95. PubMed ID: 24332641
[TBL] [Abstract][Full Text] [Related]
12. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.
Felsenstein KM; Theodorescu D
Nat Rev Urol; 2018 Feb; 15(2):92-111. PubMed ID: 29133939
[TBL] [Abstract][Full Text] [Related]
13. Molecularly-driven precision medicine for advanced bladder cancer.
Krabbe LM; Margulis V; Schrader AJ; Shariat SF; Gust KM; Boegemann M
World J Urol; 2018 Nov; 36(11):1749-1757. PubMed ID: 29948043
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
Park JC; Hahn NM
Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
[TBL] [Abstract][Full Text] [Related]
15. New generation of prognostic factors in muscle invasive bladder cancer.
Abi-Aad AS
Acta Urol Belg; 1996 May; 64(2):47-9. PubMed ID: 8701811
[No Abstract] [Full Text] [Related]
16. [Update 2016 - Immunotherapy for urothelial carcinoma].
Retz M; Gschwend JE; Schmid SC
Urologe A; 2016 Feb; 55(2):246-52. PubMed ID: 26767648
[TBL] [Abstract][Full Text] [Related]
17. Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes.
Aron M
Curr Urol Rep; 2019 Nov; 20(12):80. PubMed ID: 31781939
[TBL] [Abstract][Full Text] [Related]
18. Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond.
Mitra AP; Lerner SP
Urol Clin North Am; 2015 May; 42(2):201-15, viii. PubMed ID: 25882562
[TBL] [Abstract][Full Text] [Related]
19. Targeting Signaling Transduction Pathways in Bladder Cancer.
Abbosh PH; McConkey DJ; Plimack ER
Curr Oncol Rep; 2015 Dec; 17(12):58. PubMed ID: 26472299
[TBL] [Abstract][Full Text] [Related]
20. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
